Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Pain. 2021 Jun 1;162(6):1705–1721. doi: 10.1097/j.pain.0000000000002179

FIGURE 3.

FIGURE 3.

Inflammatory pain persisting for four or six weeks does not reduce exploratory behavior during the elevated zero maze or the open field test, nor results in locomotor deficits. White-filled data points in the REC group indicate where REC n<4 and was not compared to SAL and CFA in ordinary one-way ANOVAs or Kruskall-Wallis tests. Lines compare SAL vs. CFA, and SAL vs. REC, line ending in a bracket compares SAL vs. CFA+REC together.

A: Schematic of experimental design.

B: Paw withdrawal thresholds in the Hargreaves assay for thermal hyperalgesia by mice injected with CFA and sustaining thermal hyperalgesia for four weeks (n=10), compared with mice injected with saline (n=10).

C: Distance traveled in the open field by mice injected with CFA and sustaining thermal hyperalgesia for four weeks (n=10), compared with mice injected with saline (n=10).

D: Paw withdrawal thresholds in the Hargreaves assay for thermal hyperalgesia by mice injected with CFA and sustaining thermal hyperalgesia for six weeks (n=8), compared with mice injected with CFA which recovered (n=4), and with mice injected with saline (n=12).

E: Distance traveled in the open field by mice injected with CFA and sustaining thermal hyperalgesia for six weeks (n=6), compared with mice injected with CFA which recovered (n=4), and with mice injected with saline (n=11).

F: Entries into the open arms of the EZM by mice injected with CFA and sustaining thermal hyperalgesia for four weeks (n=10), compared with mice injected with saline (n=10).

G: Time spent in the open arms of the EZM by mice injected with CFA and sustaining thermal hyperalgesia for four weeks (n=10), compared with mice injected with saline (n=10).

H: Entries into the open arms of the EZM by mice injected with CFA and sustaining thermal hyperalgesia for six weeks (n=8), compared with mice injected with CFA which recovered (n=4), and with mice injected with saline (n=12).

I: Time spent in the open arms of the EZM by mice injected with CFA and sustaining thermal hyperalgesia for six weeks (n=8), compared with mice injected with CFA which recovered (n=4), and with mice injected with saline (n=12).

J: Entries into the center of the OFT by mice injected with CFA and sustaining thermal hyperalgesia for four weeks (n=10), compared with mice injected with saline (n=10).

K: Time spent in the center of the OFT by mice injected with CFA and sustaining thermal hyperalgesia for four weeks (n=10), compared with mice injected with saline (n=10).

L: Entries into the center of the OFT by mice injected with CFA and sustaining thermal hyperalgesia for six weeks (n=6), compared with mice injected with CFA which recovered (n=4), and with mice injected with saline (n=11).

M: Time spent in the center of the OFT by mice injected with CFA and sustaining thermal hyperalgesia for six (n=6), compared with mice injected with CFA which recovered (n=4), and with mice injected with saline (n=11).